|
|
Article: Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury.
- Article from:
- PR Newswire
- Article date:
- May 12, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Results show promising neurological recovery in severely-injured, acute cervical spinal cord injury patients treated with Cethrin
HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after treatment, 38% (5 of 13) of cervical injury ...
Related newspaper, magazine, and journal articles:
|